___________________________________________________________

For Clinical Trial information click here
Or contact the name below each study. To view more clinical trials, visit the UHC Dermatology trials page

Psoriasis Studies

Disulfiram study
Subjects: Healthy 18-60 yo with psoriasis BSA =3%, willing/able to completely abstain from alcohol throughout the study.
Study: Open-label pilot study of oral medication. Visits every 2 weeks for a total duration of ~4 months.
Contact: Mary Ann Smith ( MaryAnn.Smith@UHhospitals.org, 216-844-7164) or Jennifer Bahner (216-844-1913)

Prevalence Study
Subjects: Psoriasis patients 18+ yo as well as normal controls
Study: Evaluates cardiovascular disease risk profile in psoriasis pts and normal controls. Consent and baseline study visit, with the possibility of one additional f/u visit for both psoriasis patients and controls approx. 3-6 months later. Study visit includes vascular ultrasounds, coronary artery CT, and fasting blood draw.
Contact: Doug Kast (Doug.Kast@UHhospitals.org, 216-844-7393) or Rivka Feig (Rivka.Feig@UHhospitals.org, 216-983-5762)

OTHER STUDIES

Apremilast for Prurigo Nodularis
Subjects: Healthy =18 yo with =6-month history of prurigo nodularis who has failed 1 standard therapy (e.g. topical steroids).
Study: Open-label pilot study of oral medication. Visits every 1-2 weeks, total duration ~4 months
Contact: Mary Ann Smith (MaryAnn.Smith@UHhospitals.org, 216-844-7164) or Jennifer Bahner (216-844-1913)

CTCL STUDIES

Enzastaurin for CTCL
Subjects: =18 years of age; CTCL or sezary syndrome Stage IB to IVB disease at screening; recurrent or refractory disease after at least 1 prior therapy, 1 of which must be either bexarotene or vorinostat; visits approximately every 4 weeks after baseline visit;
Study: Open-label study of oral enzastaurin in patients with relapsed cutaneous t-cell lymphoma
Contact: Sean Carlson (sean.carlson@UHhospitals.org, 216-844-5899)

O6BG/BCNU for CTCL
Subjects: age >18 years; diagnosis of CTCL stages IA-IIA; must have failed at least on conventional treatment for CTCL other than topical corticosteroids (e.g. phototherapy, bexarotene, photopheresis, etc.); weekly visits
Study: Trial of O6Benzylguanine and topical carmustine in the treatment of refractory early-stage CTCL
Contact: Sean Carlson (sean.carlson@UHhospitals.org, 216-844-5899)

Forodesine for CTCL
Subjects: age ?18 years; diagnosis of CTCL or sezary syndrome, stages IB, IIA, IIB, III, or IVA at the screening visit; have persistent, progressive, or recurrent disease during or following treatment with at least three forms of systemic therapy, one of which must have been oral bexarotene, unless treatment with oral was not tolerated or was medically contraindicated; visits approximately every 2 weeks
Study: oral forodesine (BCX1777) in the treatment of CTCL
Contact: Sean Carlson (sean.carlson@UHhospitals.org, 216-844-5899)

 

 

CENTER NEWS

First Ever Psoriasis Legislation Introduced in Congress
National Psoriasis Foundation to ask for support of bill on Capitol Hill Day

University Hospitals
Receives $5 Million
Largest Dermatology Gift
in the U.S.

More news >>

RELATED LINKS

National Psoriasis Foundation
Non-profit organization dedicated to educating, serving and empowering people with psoriasis and psoriatic arthritis.

National Institutes of Health (NIH)
The primary Federal agency for conducting and supporting medical research.

Medline Plus
Service provided by the National Library of Medicine, the National Institutes of Health (NIH) and other government agencies and health-related organizations.